Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medicenna Therapeutics Corp ( (TSE:MDNA) ) has shared an update.
Medicenna Therapeutics announced a live webinar to discuss updated clinical data from their ABILITY-1 Phase 1/2 Study on MDNA11, both as a monotherapy and in combination with pembrolizumab. The webinar, featuring presentations from the company’s executive and scientific advisory team, aims to provide insights into the study’s findings and implications for Medicenna’s operations and industry positioning. This event underscores the company’s commitment to advancing its pipeline and engaging with stakeholders through transparent communication.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.
To see Spark’s full report on TSE:MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company specializing in the development of Superkines for treating cancer, autoimmune, and inflammatory diseases. The company focuses on creating novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, as well as first-in-class Empowered Superkines. Their products include MDNA11, a next-generation IL-2 Superkine, and MDNA113, a targeted PD-1 x IL-2 bispecific for solid tumors, developed using proprietary platforms.
Average Trading Volume: 82,750
Technical Sentiment Signal: Buy
Current Market Cap: C$108.6M
For a thorough assessment of MDNA stock, go to TipRanks’ Stock Analysis page.